300
Participants
Start Date
October 7, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
EH301 (Nicotinamide Riboside/Pterostilbene)
For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
RECRUITING
Haukeland University Hospital, Bergen
NOT_YET_RECRUITING
Nordlandssykehuset HF, Bodø
NOT_YET_RECRUITING
Vestre Viken HF, Drammen
NOT_YET_RECRUITING
Helse Førde HF, Førde
NOT_YET_RECRUITING
Helse Fonna HF, Haugesund
NOT_YET_RECRUITING
Sørlandet sykehus, Kristiansand
NOT_YET_RECRUITING
Sykehuset Innlandet HF, Lillehammer
NOT_YET_RECRUITING
Akershus University Hospital, Lørenskog
NOT_YET_RECRUITING
Helse Møre og Romsdal, Molde
NOT_YET_RECRUITING
Helse Nord-Trøndelag HF, Namsos
NOT_YET_RECRUITING
Oslo Univerity Hospital, Oslo
NOT_YET_RECRUITING
Sykehuset Østfold HF, Sarpsborg
NOT_YET_RECRUITING
Sykehuset i Telemark HF, Skien
NOT_YET_RECRUITING
Stavanger University Hospital, Stavanger
NOT_YET_RECRUITING
Universitetssykehuset Nord-Norge, Tromsø
NOT_YET_RECRUITING
St. Olavs Hospital HF, Trondheim
NOT_YET_RECRUITING
Sykehuset i Vestfold HF, Tønsberg
Collaborators (1)
Elysium Health
INDUSTRY
Haukeland University Hospital
OTHER